HCA HCA Healthcare, Inc. Common Stock
เกี่ยวกับ HCA Healthcare, Inc. Common Stock ภาพรวมบริษัทจาก Wikipedia
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
อ่านเพิ่มเติม
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
แหล่งที่มา: Wikipedia (ภาษาอังกฤษ), CC BY-SA 4.0 · ดูบน Wikipedia ↗
HCA ภาพรวมหุ้น ราคา, มูลค่าหลักทรัพย์ตามราคาตลาด, P/E, EPS, ROE, อัตราส่วนหนี้สินต่อทุน, ช่วงราคา 52 สัปดาห์
HCA กราฟราคาหุ้น OHLCV รายวันพร้อมตัวชี้วัดทางเทคนิค — แพน ซูม และปรับแต่งมุมมองของคุณ
ผลการดำเนินงาน 10 ปี แนวโน้มรายได้ กำไรสุทธิ อัตรากำไร และ EPS
การประเมินมูลค่า อัตราส่วน P/E, P/S, P/B, EV/EBITDA — หุ้นมีราคาแพงหรือถูก?
ความสามารถในการทำกำไร อัตรากำไรขั้นต้น, อัตรากำไรจากการดำเนินงาน และอัตรากำไรสุทธิ; ROE, ROA, ROIC
สุขภาพทางการเงิน หนี้สิน, สภาพคล่อง, ความสามารถในการชำระหนี้ — ความแข็งแกร่งของงบดุล
การเติบโต การเติบโตของรายได้, EPS และกำไรสุทธิ: YoY, CAGR 3 ปี, CAGR 5 ปี
ประสิทธิภาพของเงินทุน อัตราหมุนเวียนสินทรัพย์, อัตราหมุนเวียนสินค้าคงคลัง, อัตราหมุนเวียนลูกหนี้
เงินปันผล ผลตอบแทน, อัตราการจ่ายเงินปันผล, ประวัติเงินปันผล, CAGR 5 ปี
| วันที่ไม่ได้รับสิทธิปันผล | จำนวน |
|---|---|
| 16 มิถุนายน 2026 | $0.7800 |
| 17 มีนาคม 2026 | $0.7800 |
| 15 ธันวาคม 2025 | $0.7200 |
| 16 กันยายน 2025 | $0.7200 |
| 16 มิถุนายน 2025 | $0.7200 |
| 17 มีนาคม 2025 | $0.7200 |
| 13 ธันวาคม 2024 | $0.6600 |
| 16 กันยายน 2024 | $0.6600 |
| 14 มิถุนายน 2024 | $0.6600 |
| 14 มีนาคม 2024 | $0.6600 |
| 13 ธันวาคม 2023 | $0.6000 |
| 14 กันยายน 2023 | $0.6000 |
| 15 มิถุนายน 2023 | $0.6000 |
| 16 มีนาคม 2023 | $0.6000 |
| 13 ธันวาคม 2022 | $0.5600 |
| 15 กันยายน 2022 | $0.5600 |
| 15 มิถุนายน 2022 | $0.5600 |
| 16 มีนาคม 2022 | $0.5600 |
| 13 ธันวาคม 2021 | $0.4800 |
| 15 กันยายน 2021 | $0.4800 |
HCA ความเห็นหลายต่อหลายของนักวิเคราะห์ มุมมองนักวิเคราะห์ทั้งเชิงบวกและเชิงลบ, ราคาเป้าหมาย 12 เดือน, อัพไซด์
- ซื้อแนะนำ 6 20.0%
- ซื้อ 11 36.7%
- ถือ 12 40.0%
- ขาย 1 3.3%
- ขายแนะนำ 0 0.0%
ราคาเป้าหมาย 12 เดือน
21 นักวิเคราะห์ · 2026-08-17ประวัติผลประกอบการ EPS จริงเทียบกับประมาณการ, เปอร์เซ็นต์ส่วนต่าง%, อัตราการชนะ, วันประกาศผลประกอบการครั้งถัดไป
| งวด | EPS Actual | EPS คาด | ส่วนต่าง |
|---|---|---|---|
| 30 มิถุนายน 2026 | $7.62 | $7.54 | 0.08% |
| 31 มีนาคม 2026 | $7.15 | $7.21 | -0.06% |
| 31 ธันวาคม 2025 | $8.14 | $7.53 | 0.61% |
| 30 กันยายน 2025 | $6.96 | $5.77 | 1.2% |
| 30 มิถุนายน 2025 | $6.83 | $6.31 | 0.52% |
| 31 มีนาคม 2025 | $6.45 | $5.84 | 0.61% |
การเปรียบเทียบกับบริษัทคู่เทียบ (อุตสาหกรรมย่อย GICS) เมตริกสำคัญเทียบกับบริษัทในกลุ่มอุตสาหกรรมเดียวกัน
| Ticker | มูลค่าตลาด | P/E | รายได้ YoY | อัตรากำไรสุทธิ | ROE | อัตรากำไรขั้นต้น |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SGRY | $2.00B | -25.3 | 6.2% | -2.4% | -4.5% | — |
ปัจจัยพื้นฐานฉบับเต็ม ตัวชี้วัดทั้งหมดรายปี — งบกำไรขาดทุน, งบดุล, งบกระแสเงินสด
งบกำไรขาดทุน 12
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
งบดุล 22
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
กระแสเงินสด 17
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
ความสามารถในการทำกำไร 5
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
สภาพคล่องและความสามารถในการชำระหนี้ 4
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
ประสิทธิภาพ 2
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
อัตราการเติบโต 10
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
การประเมินมูลค่า (TTM) 17
| ตัวชี้วัด | แนวโน้ม | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
งบกำไรขาดทุน 12
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
งบดุล 20
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
กระแสเงินสด 16
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
ความสามารถในการทำกำไร 5
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
สภาพคล่องและความสามารถในการชำระหนี้ 4
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
ประสิทธิภาพ 2
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
การประเมินมูลค่า (TTM) 14
| ตัวชี้วัด | แนวโน้ม | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
งบการเงิน งบกำไรขาดทุน, งบดุล, งบกระแสเงินสด — รายปี, 5 ปีล่าสุด
งบกำไรขาดทุน
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| รายได้ | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| กำไรสุทธิ | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| EPS ที่ปรับลดแล้ว | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
งบดุล
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| หนี้สินต่อทุน | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| อัตราส่วนสภาพคล่อง | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| อัตราส่วนเงินสด | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
กระแสเงินสด
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| กระแสเงินสดอิสระ | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
ข่าวล่าสุด หัวข้อข่าวล่าสุดที่กล่าวถึงบริษัทนี้
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- กิจกรรมออปชันที่น่าสังเกตในวันพฤหัสบดี: HCA, HRTG, ZM
- กลยุทธ์การระดมทุนของ HCA Healthcare (HCA) ขยายตัว – นี่คือวิธีการ
- HCA Healthcare ทำกำไรรายไตรมาสเกินคาดจากความต้องการบริการทางการแพทย์
ตัวชี้วัดของฉัน รายการเฝ้าดูส่วนตัวของคุณ — แถวที่เลือกจากข้อมูลพื้นฐานฉบับเต็ม
เลือกเมตริกที่สำคัญสำหรับคุณ — คลิก ➕ ถัดจากแถวใดก็ได้ในข้อมูลพื้นฐานฉบับเต็มด้านบน
การเลือกของคุณถูกบันทึกและจะติดตามคุณไปในทุกสัญลักษณ์หุ้น
ผู้ถือครองสถาบัน (13F) 1,486 รายงาน · $39.4B ทั้งหมด · ณ วันที่ 30 มิถุนายน 2026
สถาบันที่รายงานการถือครองหุ้นนี้ในเอกสาร SEC Form 13F รายไตรมาสของตน เฉพาะสถานะ Long; ผู้ยื่นคำร้องรายเดียวอาจปรากฏสองครั้งสำหรับสัญญาออปชันที่แยกจากกัน ขา put/call ขนาดใหญ่ที่หักล้างกันมักสะท้อนถึงการทำตลาด (market-making) หรือสินค้าคงคลังที่มีการป้องกันความเสี่ยง (hedged inventory) ไม่ใช่การเชื่อมั่นในทิศทาง
| พอร์ตใหม่ | ตำแหน่งที่ปิดไปแล้ว | เพิ่มขึ้น | ลดลง | การเปลี่ยนแปลงสุทธิของจำนวนหุ้น |
|---|---|---|---|---|
| 128 (-51 เทียบกับไตรมาสก่อน) | 174 (+70 เทียบกับไตรมาสก่อน) | 450 (-30 เทียบกับไตรมาสก่อน) | 555 (-4 เทียบกับไตรมาสก่อน) | +16.3M |
เปรียบเทียบกับ Q1 2026. การยื่นแบบฟอร์ม 13F ของ SEC จะครบกำหนดภายใน 45 วันนับจากสิ้นสุดไตรมาส บวกกับระยะเวลาผ่อนผันสั้นๆ สำหรับผู้ยื่นล่าช้า — ไตรมาสที่ยังอยู่ในช่วงเวลานี้จะถูกข้ามไปเพื่อใช้คู่ที่รายงานล่าสุดอย่างสมบูรณ์
| สถาบัน | มูลค่า | หุ้น | % ของ 13F ที่ติดตาม | ประเภท |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6,118,113,464 | 13,104,814 | 15.52% | หุ้น |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,954,150,533 | 10,141,708 | 10.03% | หุ้น |
| Sanders Capital, LLC | $3,442,060,818 | 8,828,287 | 8.73% | หุ้น |
| STATE STREET CORP | $2,912,102,056 | 7,469,035 | 7.39% | หุ้น |
| WELLINGTON MANAGEMENT GROUP LLP | $1,750,298,867 | 4,489,212 | 4.44% | หุ้น |
| GEODE CAPITAL MANAGEMENT, LLC | $1,225,259,672 | 3,159,159 | 3.11% | หุ้น |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,057,704,509 | 2,712,828 | 2.68% | หุ้น |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861,456,107 | 2,209,485 | 2.19% | หุ้น |
| NORGES BANK | $836,457,140 | 2,145,367 | 2.12% | หุ้น |
| Capital World Investors | $770,864,224 | 1,977,121 | 1.96% | หุ้น |
| Capital International Investors | $747,403,041 | 1,916,947 | 1.90% | หุ้น |
| Crake Asset Management LLP | $449,072,183 | 1,151,792 | 1.14% | หุ้น |
| Metropolis Capital Ltd | $430,915,307 | 910,564 | 1.09% | หุ้น |
| Darsana Capital Partners LP | $428,879,000 | 1,100,000 | 1.09% | หุ้น |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414,533,777 | 1,063,207 | 1.05% | หุ้น |
| Life Cycle Investment Partners Ltd | $355,737,196 | 912,404 | 0.90% | หุ้น |
| VANGUARD FIDUCIARY TRUST CO | $339,685,814 | 871,235 | 0.86% | หุ้น |
| FMR LLC | $325,199,295 | 834,080 | 0.83% | หุ้น |
| BARCLAYS PLC | $299,888,573 | 769,162 | 0.76% | หุ้น |
| LYRICAL ASSET MANAGEMENT LP | $255,015,742 | 654,071 | 0.65% | หุ้น |
| BlackRock, Inc. | $240,062,291 | 615,718 | 0.61% | หุ้น |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235,649,908 | 604,401 | 0.60% | หุ้น |
| National Pension Service | $230,650,346 | 591,578 | 0.59% | หุ้น |
| NORDEA INVESTMENT MANAGEMENT AB | $230,189,125 | 594,466 | 0.58% | หุ้น |
| GOLDMAN SACHS GROUP INC | $209,775,669 | 538,038 | 0.53% | หุ้น |
| Gobi Capital LLC | $195,742,325 | 502,045 | 0.50% | หุ้น |
| Cryder Capital Partners LLP | $194,561,738 | 499,017 | 0.49% | หุ้น |
| Swiss National Bank | $172,097,446 | 441,400 | 0.44% | หุ้น |
| AustralianSuper Pty Ltd | $159,635,782 | 409,438 | 0.41% | หุ้น |
| Consulta Ltd | $155,956,000 | 400,000 | 0.40% | หุ้น |
| LEE DANNER & BASS INC | $152,150,679 | 390,240 | 0.39% | หุ้น |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151,472,265 | 388,500 | 0.38% | สัญญาซื้อล่วงหน้า |
| Mitsubishi UFJ Asset Management Co., Ltd. | $147,943,761 | 379,450 | 0.38% | หุ้น |
| DIMENSIONAL FUND ADVISORS LP | $139,697,405 | 358,300 | 0.35% | หุ้น |
| Vanguard Global Advisers, LLC | $136,962,509 | 351,285 | 0.35% | หุ้น |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $134,838,505 | 288,820 | 0.34% | หุ้น |
| ALLIANCEBERNSTEIN L.P. | $134,459,788 | 284,126 | 0.34% | หุ้น |
| Sumitomo Mitsui Trust Group, Inc. | $132,794,974 | 340,596 | 0.34% | หุ้น |
| TD Asset Management Inc | $131,847,152 | 338,165 | 0.33% | หุ้น |
| Legal & General Group Plc | $127,805,162 | 327,798 | 0.32% | หุ้น |
| California Public Employees Retirement System | $124,133,958 | 318,382 | 0.31% | หุ้น |
| LAZARD ASSET MANAGEMENT LLC | $120,619,879 | 309,369 | 0.31% | หุ้น |
| JANE STREET GROUP, LLC | $119,540,274 | 306,600 | 0.30% | สัญญาซื้อล่วงหน้า |
| VANGUARD ASSET MANAGEMENT, Ltd | $116,069,863 | 297,699 | 0.29% | หุ้น |
| CAPTRUST FINANCIAL ADVISORS | $114,741,071 | 294,291 | 0.29% | หุ้น |
| ANTIPODES PARTNERS Ltd | $113,045,096 | 289,941 | 0.29% | หุ้น |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $109,718,328 | 231,845 | 0.28% | หุ้น |
| CITADEL ADVISORS LLC | $105,660,190 | 271,000 | 0.27% | สัญญาซื้อล่วงหน้า |
| RHUMBLINE ADVISERS | $97,580,413 | 250,277 | 0.25% | หุ้น |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $97,026,076 | 248,855 | 0.25% | หุ้น |
| MACKENZIE FINANCIAL CORP | $93,597,383 | 240,061 | 0.24% | หุ้น |
| BloombergSen Inc. | $93,160,317 | 238,940 | 0.24% | หุ้น |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92,247,974 | 236,600 | 0.23% | สัญญาขายล่วงหน้า |
| Brandywine Global Investment Management, LLC | $89,380,814 | 191,451 | 0.23% | หุ้น |
| BANK OF AMERICA CORP /DE/ | $89,069,981 | 228,449 | 0.23% | หุ้น |
| NEUBERGER BERMAN GROUP LLC | $85,926,216 | 220,386 | 0.22% | หุ้น |
| MILFORD FUNDS LTD | $82,165,029 | 210,739 | 0.21% | หุ้น |
| Bridgewater Associates, LP | $79,227,208 | 203,204 | 0.20% | หุ้น |
| Prana Capital Management, LP | $75,552,494 | 193,779 | 0.19% | หุ้น |
| DANSKE BANK A/S | $73,238,497 | 187,844 | 0.19% | หุ้น |
| FRANKLIN RESOURCES INC | $70,965,828 | 182,015 | 0.18% | หุ้น |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $70,445,715 | 180,681 | 0.18% | หุ้น |
| Quantinno Capital Management LP | $70,407,055 | 180,581 | 0.18% | หุ้น |
| ARGENT CAPITAL MANAGEMENT LLC | $69,149,681 | 177,357 | 0.18% | หุ้น |
| Retirement Systems of Alabama | $68,081,812 | 174,618 | 0.17% | หุ้น |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $66,167,842 | 169,709 | 0.17% | หุ้น |
| BNP PARIBAS FINANCIAL MARKETS | $64,793,090 | 166,183 | 0.16% | หุ้น |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $64,665,206 | 165,855 | 0.16% | หุ้น |
| HSBC HOLDINGS PLC | $64,431,534 | 165,332 | 0.16% | หุ้น |
| AVIVA PLC | $64,264,789 | 164,828 | 0.16% | หุ้น |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $64,194,533 | 135,649 | 0.16% | หุ้น |
| SEB Asset Management AB | $63,257,255 | 162,244 | 0.16% | หุ้น |
| TODD ASSET MANAGEMENT LLC | $62,567,208 | 160,474 | 0.16% | หุ้น |
| Swedbank AB | $62,528,998 | 160,376 | 0.16% | หุ้น |
| W1M Investment Management Ltd | $61,247,490 | 143,647 | 0.16% | หุ้น |
| HARRIS ASSOCIATES L P | $60,080,879 | 154,097 | 0.15% | หุ้น |
| Ensign Peak Advisors, Inc | $58,372,381 | 149,715 | 0.15% | หุ้น |
| NEW YORK STATE COMMON RETIREMENT FUND | $57,747,778 | 148,113 | 0.15% | หุ้น |
| CITADEL ADVISORS LLC | $57,235,852 | 146,800 | 0.15% | สัญญาขายล่วงหน้า |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57,160,993 | 146,800 | 0.15% | หุ้น |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $56,512,217 | 144,944 | 0.14% | หุ้น |
| Pictet Asset Management Holding SA | $52,147,803 | 133,739 | 0.13% | หุ้น |
| VICTORY CAPITAL MANAGEMENT INC | $50,752,761 | 130,172 | 0.13% | หุ้น |
| Pentwater Capital Management LP | $50,685,700 | 130,000 | 0.13% | หุ้น |
| D. E. Shaw & Co., Inc. | $50,554,307 | 129,663 | 0.13% | หุ้น |
| APG Asset Management N.V. | $50,368,550 | 147,699 | 0.13% | หุ้น |
| AMF Tjanstepension AB | $50,355,853 | 129,154 | 0.13% | หุ้น |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $50,349,225 | 129,137 | 0.13% | หุ้น |
| EQUITABLE TRUST CO | $49,147,974 | 126,056 | 0.12% | หุ้น |
| ENVESTNET ASSET MANAGEMENT INC | $48,919,124 | 125,469 | 0.12% | หุ้น |
| CANADA PENSION PLAN INVESTMENT BOARD | $48,197,812 | 123,619 | 0.12% | หุ้น |
| AMERICAN CENTURY COMPANIES INC | $47,460,140 | 121,727 | 0.12% | หุ้น |
| OpenArc Corporate Advisory, LLC | $47,210,610 | 121,087 | 0.12% | หุ้น |
| L1 Capital International Pty Ltd | $46,121,648 | 118,294 | 0.12% | หุ้น |
| FIRST TRUST ADVISORS LP | $44,251,579 | 113,498 | 0.11% | หุ้น |
| PFA Pension, Forsikringsaktieselskab | $44,046,098 | 112,971 | 0.11% | หุ้น |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $43,830,264 | 112,417 | 0.11% | หุ้น |
| EP Wealth Advisors, LLC | $43,287,826 | 111,026 | 0.11% | หุ้น |
| WOLVERINE TRADING, LLC | $42,597,104 | 101,200 | 0.11% | สัญญาซื้อล่วงหน้า |
| MERCER GLOBAL ADVISORS INC /ADV | $42,302,070 | 108,497 | 0.11% | หุ้น |
ผู้บริหารบริษัท 91 รายชื่อผู้บริหาร · ผู้บริหาร 54 คน · กรรมการ 31 คน
| ผู้บริหารภายใน | บทบาท | กิจกรรมล่าสุด | หุ้นที่ถือครอง | ซื้อ 12 เดือน | ขาย 12 เดือน | สุทธิ 12 เดือน |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 กุมภาพันธ์ 2026 F | 64,842 | 0 | 7 | $-21,483,290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 กุมภาพันธ์ 2013 A | 21,429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 7 พฤษภาคม 2026 G | 46,576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 กุมภาพันธ์ 2024 F | 22,251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 พฤศจิกายน 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 พฤศจิกายน 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 พฤศจิกายน 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 1 กรกฎาคม 2005 F | 13,865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 พฤศจิกายน 2024 M | 6,843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 กรกฎาคม 2024 M | 27,008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 กุมภาพันธ์ 2024 F | 17,936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 พฤศจิกายน 2022 M | 202,443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 พฤศจิกายน 2022 S | 30,807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 ธันวาคม 2012 A | 335,657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2 พฤศจิกายน 2011 M | 144,714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 กรกฎาคม 2006 A | 62,173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 ตุลาคม 2005 A | 26,154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 ตุลาคม 2004 D | 9,029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 7 พฤษภาคม 2004 D | 24,177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 กุมภาพันธ์ 2026 F | 23,062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 13 กุมภาพันธ์ 2026 M | 8,853 | 0 | 2 | $-2,747,520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 กุมภาพันธ์ 2026 S | 11,993 | 0 | 2 | $-4,126,932 |
| Christopher F. Wyatt | SVP & Controller | 11 กุมภาพันธ์ 2026 S | 44,379 | 0 | 1 | $-2,020,000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 กุมภาพันธ์ 2026 F | 10,407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 กุมภาพันธ์ 2026 F | 32,080 | 0 | 1 | $-747,135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 กุมภาพันธ์ 2025 F | 11,113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 พฤศจิกายน 2024 S | 9,454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 พฤศจิกายน 2024 M | 52,702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 5 สิงหาคม 2024 G | 18,526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 กรกฎาคม 2024 S | 3,510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 กรกฎาคม 2024 S | 17,755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 9 พฤษภาคม 2024 S | 5,185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 มีนาคม 2024 M | 1,576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 เมษายน 2023 M | 24,643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 9 พฤศจิกายน 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 5 พฤษภาคม 2021 S | 50,062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 กุมภาพันธ์ 2021 F | 5,578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 กุมภาพันธ์ 2021 F | 10,122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 1 พฤษภาคม 2019 A | 194,145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 กุมภาพันธ์ 2019 M | 84,157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 กุมภาพันธ์ 2019 M | 881,823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 กุมภาพันธ์ 2018 M | 7,003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 กุมภาพันธ์ 2018 M | 35,546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 กุมภาพันธ์ 2018 M | 65,199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 พฤษภาคม 2017 M | 26,378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 7 พฤศจิกายน 2016 M | 110,167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 กุมภาพันธ์ 2016 A | 51,965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 พฤษภาคม 2012 M | 299,030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 6 ตุลาคม 2009 A | 188,340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 กุมภาพันธ์ 2009 M | 13,092 | 0 | 0 | $0 |
ผู้บริหารจากเอกสาร SEC Form 3/4/5; สุทธิ = เฉพาะการซื้อขายในตลาดเปิด
นักเคลื่อนไหวและเจ้าของ %+ 5 4 รายการ
นักลงทุนที่ยื่น SEC Schedule 13D — กรรมสิทธิ์ตามผลประโยชน์ที่แท้จริงสูงกว่า % 5 โดยมีเจตนาที่จะมีอิทธิพลต่อผู้ออกหลักทรัพย์ (การถือหุ้นของนักเคลื่อนไหว, การรณรงค์ในคณะกรรมการ, M&A) แต่ละแถวแสดงสถานะล่าสุดที่ทราบของตำแหน่งของผู้ยื่นคำร้องรายนั้น
| ผู้ยื่นคำร้อง | ยื่นแล้ว | ส่วนได้เสีย | สถานะ | วัตถุประสงค์ | การยื่นคำร้อง |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 กุมภาพันธ์ 2026 | 31.60% | การยื่นคำร้องครั้งแรก | — | SEC |
| 22 พฤศจิกายน 2006 | — | การยื่นคำร้องครั้งแรก | — | SEC | |
| Merrill Lynch Bank USA | 11 กันยายน 2006 | — | การยื่นคำร้องครั้งแรก | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 4 สิงหาคม 2006 | — | การยื่นคำร้องครั้งแรก | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
การถือครอง ETF ถือโดย ETF 207 ราย
น้ำหนักสะท้อนถึงการถือครองหุ้นโดยตรง (N-PORT) เท่านั้น กองทุนเลเวอเรจหรือกองทุนที่อิงตราสารอนุพันธ์อาจมีการเปิดรับความเสี่ยงจากสัญญาแลกเปลี่ยน (swap) เพิ่มเติมซึ่งไม่แสดง
| กองทุน | น้ำหนัก | หน่วย | ณ วันที่ | แหล่งที่มา |
|---|---|---|---|---|
| IHF · iShares Trust | 4.67% | 141,320 SH | 8 สิงหาคม 2026 | รายวัน |
| BUL · Pacer Funds Trust | 3.91% | 11,437 NS | 30 เมษายน 2026 | N-PORT |
| YALL · Tidal Trust I | 3.61% | 9,261 NS | 31 พฤษภาคม 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3.02% | 1,646 NS | 31 พฤษภาคม 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2.32% | 99,335 SH | 8 สิงหาคม 2026 | รายวัน |
| ABIG · EA Series Trust | 2.00% | 2,938 NS | 29 พฤษภาคม 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.99% | 39,985 NS | 30 เมษายน 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.67% | 31,685 SH | 8 สิงหาคม 2026 | รายวัน |
| COWZ · Pacer Funds Trust | 1.64% | 688,264 NS | 30 เมษายน 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.64% | 1,762 NS | 30 เมษายน 2026 | N-PORT |
| FEGE · RBB Fund Trust | 1.46% | 74,706 NS | 31 พฤษภาคม 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.39% | 60,385 SH | 8 สิงหาคม 2026 | รายวัน |
| RPG · Invesco Exchange-Traded Fund Trust | 1.30% | 63,448 SH | 8 สิงหาคม 2026 | รายวัน |
| TMFE · RBB Fund, Inc. | 1.29% | 2,892 NS | 31 พฤษภาคม 2026 | N-PORT |
| AMID · EA Series Trust | 1.23% | 3,402 NS | 29 พฤษภาคม 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.15% | 7,180 NS | 30 เมษายน 2026 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1.12% | 6,544 NS | 30 เมษายน 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1.12% | 73,639 NS | 30 เมษายน 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1.10% | 4,883 NS | 30 เมษายน 2026 | N-PORT |
| IYH · iShares Trust | 0.99% | 89,420 SH | 8 สิงหาคม 2026 | รายวัน |
| NEAR · iShares U.S. ETF Trust | 0.99% | 48,109,000 SH | 8 สิงหาคม 2026 | รายวัน |
| CURE · Direxion Shares ETF Trust | 0.98% | 3,122 NS | 30 เมษายน 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.90% | 470,451 SH | 8 สิงหาคม 2026 | รายวัน |
| NFRA · FlexShares Trust | 0.88% | 62,176 NS | 30 เมษายน 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0.87% | 5,693 NS | 30 เมษายน 2026 | N-PORT |
| RXL · ProShares Trust | 0.86% | 1,632 NS | 31 พฤษภาคม 2026 | N-PORT |
| DIVB · iShares Trust | 0.85% | 36,806 SH | 8 สิงหาคม 2026 | รายวัน |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.82% | 24,078,000 | 8 สิงหาคม 2026 | รายวัน |
| LSEQ · Harbor ETF Trust | 0.81% | 285 NS | 30 เมษายน 2026 | N-PORT |
| IXJ · iShares Trust | 0.80% | 81,465 SH | 8 สิงหาคม 2026 | รายวัน |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.76% | 26,493,000 | 8 สิงหาคม 2026 | รายวัน |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.74% | 2,335 SH | 8 สิงหาคม 2026 | รายวัน |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.73% | 21,329 NS | 30 เมษายน 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 0.68% | 533 NS | 31 พฤษภาคม 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.68% | 2,698 NS | 30 เมษายน 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.67% | 12,075 SH | 8 สิงหาคม 2026 | รายวัน |
| VCEB · VANGUARD WORLD FUND | 0.62% | 8,146,000 PA | 8 สิงหาคม 2026 | รายวัน |
| FDMO · FIDELITY COVINGTON TRUST | 0.61% | 11,771 NS | 30 เมษายน 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0.58% | 72,768 NS | 30 เมษายน 2026 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund VI… | 0.56% | 9,664 NS | 31 พฤษภาคม 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.55% | 11,876 SH | 8 สิงหาคม 2026 | รายวัน |
| VLLU · Harbor ETF Trust | 0.54% | 54 NS | 30 เมษายน 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.53% | 7,404 NS | 30 เมษายน 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0.51% | 844 NS | 30 เมษายน 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0.50% | 4,620 NS | 31 พฤษภาคม 2026 | N-PORT |
| AKAF · ETF Series Solutions | 0.50% | 39 NS | 31 พฤษภาคม 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.50% | 22,679,000 | 8 สิงหาคม 2026 | รายวัน |
| ROUS · Lattice Strategies Trust | 0.47% | 6,388 NS | 30 เมษายน 2026 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0.46% | 54,218,000 PA | 8 สิงหาคม 2026 | รายวัน |
| CGGR · Capital Group Growth ETF | 0.45% | 290,273 NS | 31 พฤษภาคม 2026 | N-PORT |